BIOLOGIC EFFECTS OF RECOMBINANT HIRUDIN (CGP-39393) IN HUMAN VOLUNTEERS

被引:68
作者
VERSTRAETE, M
NURMOHAMED, M
KIENAST, J
SIEBECK, M
SILLINGENGELHARDT, G
BULLER, H
HOET, B
BICHLER, J
CLOSE, P
BREDDIN, JHK
MARBET, GA
SCHRAMM, W
TENCATE, JW
BULLER, HR
NURMOHAMED, MT
ARNOUT, J
HOET, B
SPANNAGL, M
RING, J
FRITZ, H
VANDELOO, J
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS
[2] UNIV MUNSTER,INNERE MED KLIN,W-4400 MUNSTER,GERMANY
[3] UNIV MUNICH,CHIRURG KLIN INNENSTADT,W-8000 MUNICH 2,GERMANY
[4] UNIV MUNICH,INST KLIN CHEM & BIOCHEM,W-8000 MUNICH 2,GERMANY
[5] CIBA GEIGY AG,DIV PHARMA,CH-4002 BASEL,SWITZERLAND
[6] UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS
[7] UNIV MUNICH,MED KLIN INNENSTADT,W-8000 MUNICH 70,GERMANY
[8] UNIV MUNICH,DERMATOL KLIN & POLIKLIN,W-8000 MUNICH 2,GERMANY
[9] UNIV MUNICH,INST KLIN CHEM & BIOCHEM,W-8000 MUNICH 2,GERMANY
关键词
D O I
10.1016/0735-1097(93)90419-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The purpose of this study was to investigate the biologic efficacy and pharmacokinetics of different doses of recombinant hirudin administered in single or repeated subcutaneous injections in healthy volunteers. Background. Hirudin is a highly specific inhibitor of thrombin, the pivotal enzyme in thrombosis. Differences between hirudin and heparin in experimental animals indicate that hirudin may be a superior antithrombotic drug in humans. Methods. The biologic effect of recombinant desulfato-hirudin (CGP 39393) administered as single or repeated (every 8 h for 3 days or every 12 h for 6 days) subcutaneous injections was studied in 231 healthy human volunteers. Results. Single subcutaneous doses of 0.1, 0.2, 0.3, 0.4, 0.5 and 0.75 mg/kg body weight in 195, 8, 12, 8, 4 and 4 volunteers, respectively, prolonged the activated partial thromboplastin time in a dose-proportional fashion within the 1st 30 min, with a near-maximal effect for 3 to 4 h after the dose. The mean activated partial thromboplastin time increased to 1.48 and 1.93 times baseline values 30 min after single subcutaneous injections of 0.2 and 0.4 mg/kg of CGP 39393, respectively. There was a linear relation over a wide range between the activated partial thromboplastin time prolongation and plasma concentrations of CGP 39393. Plasma clearance was between 1.5 and 1.7 ml/min per kg. The subcutaneous administration of 0.3 and 0.5 mg recombinant hirudin three times a day for 3 days or two times a day for 6 days prolonged the activated partial thromboplastin time by 1.71 to 1.69 and 1.78 to 1.92 times baseline levels, respectively, with the preinjection values maintained in the hypocoagulable range. No prolongation of bleeding time was measured at peak plasma hirudin levels. Because thrombin and prothrombin times are not able to reflect high or low CGP 39393 concentrations, respectively, neither test is suitable for monitoring administration of this drug. Conclusions. CGP 39393 appears to be well tolerated in volunteers, even after repeated doses. The activated partial thromboplastin time test seems to be well suited to monitor the anticoagulant effect of recombinant hirudin because the dose effect is linear up to 0.5 mg/kg of subcutaneous CGP 39393. The prolongation of activated partial thromboplastin time after subcutaneous injection of CGP 39393 shows a plateau lasting for 3 h. Further studies are now required to determine the dose that will provide the best antithrombotic effect and the lowest bleeding tendency in arterial or venous thrombosis indications.
引用
收藏
页码:1080 / 1088
页数:9
相关论文
共 29 条
[1]  
BICHLER J, 1988, ARZNEIMITTEL-FORSCH, V38-1, P704
[2]  
BRAUNWALD E, 1992, 8TH INT WORKSH GEORG
[3]  
CLOSE P, 1993, IN PRESS COR ART DIS
[4]   THROMBIN IS AN IMPORTANT MEDIATOR OF PLATELET-AGGREGATION IN STENOSED CANINE CORONARY-ARTERIES WITH ENDOTHELIAL INJURY [J].
EIDT, JF ;
ALLISON, P ;
NOBLE, S ;
ASHTON, J ;
GOLINO, P ;
MCNATT, J ;
BUJA, LM ;
WILLERSON, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (01) :18-27
[5]  
ERIKSSON BI, 1992, CIRCULATION, V86, P410
[6]  
FRUEH F, B1251988 CIB GEIG DA
[7]   INTERRUPTION OF ACUTE PLATELET-DEPENDENT THROMBOSIS BY THE SYNTHETIC ANTITHROMBIN D-PHENYLALANYL-L-PROLYL-L-ARGINYL CHLOROMETHYL KETONE [J].
HANSON, SR ;
HARKER, LA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (09) :3184-3188
[8]   EFFECTS OF THROMBIN INHIBITION ON THE DEVELOPMENT OF ACUTE PLATELET-THROMBUS DEPOSITION DURING ANGIOPLASTY IN PIGS - HEPARIN VERSUS RECOMBINANT HIRUDIN, A SPECIFIC THROMBIN INHIBITOR [J].
HERAS, M ;
CHESEBRO, JH ;
PENNY, WJ ;
BAILEY, KR ;
BADIMON, L ;
FUSTER, V .
CIRCULATION, 1989, 79 (03) :657-665
[9]   HIRUDIN, HEPARIN, AND PLACEBO DURING DEEP ARTERIAL INJURY IN THE PIG - THE INVIVO ROLE OF THROMBIN IN PLATELET-MEDIATED THROMBOSIS [J].
HERAS, M ;
CHESEBRO, JH ;
WEBSTER, MWI ;
MRUK, JS ;
GRILL, DE ;
PENNY, WJ ;
BOWIE, EJW ;
BADIMON, L ;
FUSTER, V .
CIRCULATION, 1990, 82 (04) :1476-1484
[10]   RECOMBINANT HIRUDIN REDUCES THE INCIDENCE OF THROMBOTIC OCCLUSION IN A CANINE MODEL OF CORONARY VASCULAR INJURY [J].
HOMEISTER, JW ;
MICKELSON, JK ;
HOFF, PT ;
LUCCHESI, BR .
CORONARY ARTERY DISEASE, 1991, 2 (02) :237-246